Led · Equity · Aug 2023

Travelshift is a leading Icelandic online travel agency (OTA) that specializes in technology-driven travel solutions. It recently launched Guide to Europe, an AI-powered travel platform that allows travelers to book everything in one checkout and manage their entire journey in one app. The Guide to Europe gives travelers access to thousands of itineraries optimized with AI and the company says it now offers the world’s largest selection of vacation packages in Europe. Travelshift plans to accelerate growth and continue building the next generation of travel through innovative use of AI to deliver personalized and seamless experiences. The company has over a decade of experience in the industry. Financially, Travelshift raised $10 million from existing shareholders in its latest round, bringing total funding to $30 million.

Led · Series B · Apr 2016

EdCast is an AI-powered Knowledge Cloud that provides unified discovery, personalized learning, and knowledge management for enterprise customers. Its offerings include a Learning Experience Platform (LXP), a Content Marketplace, and MyGuide in-app guides, intelligence and automation for business software. The platform integrates with Google Search, Microsoft Office, Microsoft Teams, Salesforce, Slack, ServiceNow, VMware and others to deliver learning in the flow of work. EdCast’s award-winning platform is used by Global 2000 companies and large government organizations, including Hewlett Packard Enterprise, Dell EMC, ANZ Bank, Schneider Electric, Jefferson Health, Mars Inc., NASSCOM, and the World Economic Forum. It serves two million paid users and aims to expand its Knowledge Cloud, Content Marketplace, and MyGuide products. The company also plans to continue hiring across sales, marketing, and product engineering to support its customer growth. EdCast’s core product is the Knowledge Cloud platform, which provides AI-powered contextual content and personalized learning in the flow of work across business applications such as Microsoft Office365, ServiceNow, Salesforce and Slack. The company offers a Learning Experience Platform (LXP) and MyGuide in-app guides, intelligence and automation for business software. EdCast operates a ContentExchange marketplace that includes partners like edX.org, Regis Group, Harvard ManageMentor, Mandel Communications and Intuition. The company announced an integration with Box and said it will announce additional integrations in Q1 2019. EdCast reported it has surpassed two million paid users across hundreds of enterprise and public-sector customers, including HPE, Dell EMC, Schneider Electric, ANZ Bank, Jefferson Health and others. The announcement framed the product as supporting a broader enterprise shift to cloud and AI-powered upskilling solutions amid rising corporate demand for training. EdCast builds the EdCast Knowledge Media & Intelligence Network, delivering curated, contextual bite-size insights (SmartBites) and live access to influencers and subject-matter experts. Its platform powers social, mobile and cloud-based informal learning for enterprises, institutions, governments and nonprofits. The company positions itself to enable lifelong learning for individuals, teams and organizations and is targeting workplace millennials while expanding into telecom, banking, media and retail. EdCast counts large enterprise customers and partnerships, including HP (powering HP LIFE), GE, Salesforce and EMC; HP LIFE reaches a knowledge community of over 500,000 users worldwide. The company is a Stanford StartX company advised by visionaries such as Mitch Kapor and Professor Jeffrey Sachs. Financially, EdCast has completed a $16 million Series B following a prior $6 million Series A in late 2014. EdCast builds a Knowledge Cloud and personal learning network that powers online learning portals built on OpenEdX for institutions, enterprises, governments and non-profits. The platform is designed to enable collaboration among educators, students and employers and to scale to millions of learners. The company is pursuing a "multiversity" vision to interconnect hundreds of campuses through public and private hosted clouds to deliver the best curriculum globally. EdCast has announced partnerships including a project with the United Nations’ Sustainable Development Solutions Network linking over 200 institutions and engagement with the Open Education Consortium's 300+ member institutions. Financially, EdCast has just completed a $6 million Series A financing led by SoftBank Capital. The team is led by founder and CEO Karl Mehta, formerly founder & CEO of PlaySpan (acquired by Visa), and the company is based in Mountain View, California.

Participated · Equity · Apr 2013

Vapotherm develops and manufactures advanced, noninvasive respiratory care technologies, including its High Flow Therapy system. The company says its High Flow Therapy has treated over 700,000 patients. Vapotherm is based in Exeter, New Hampshire and is privately held. Management states the company focuses on improving clinical and economic outcomes for patients and customers. Vapotherm plans to expand its U.S. field organization, develop new products, and expand in select international markets. The recent financing is intended to fund those expansion and product development efforts. Vapotherm develops and manufactures advanced, noninvasive respiratory care technologies, including its High Flow Therapy system. The company is focused on improving clinical outcomes for patients with chronic and acute breathing disorders. Vapotherm is privately held and based in Exeter, New Hampshire. Management says the new capital will be used to continue building out a direct sales organization in the U.S. and to develop next-generation solutions. Over 700,000 patients have been treated with Vapotherm High Flow Therapy, indicating adoption at scale. The company closed a $20 million equity financing to support these growth plans. Vapotherm manufactures advanced, noninvasive respiratory care devices and high-flow therapy systems. The company is led by President & CEO Joe Army and focuses on respiratory support for patients with chronic or acute breathing disorders. Vapotherm has treated over 600,000 patients with its high flow therapy. It closed a $24M financing to support growth and improve healthcare for patients worldwide. In conjunction with the financing, a partner from the lead investor joined Vapotherm’s Board of Directors. The company intends to deploy the funds to expand and enhance its products and patient impact. Vapotherm manufactures advanced respiratory care devices and develops noninvasive technologies for supporting patients with chronic or acute breathing disorders. The company is led by founder Bill Niland and President & CEO Joe Army. It is based in Exeter, New Hampshire, and has an experienced board including James “Jim” Liken, a board member since April 2010 who will serve as Chairman. Vapotherm closed a $29M financing to support its operations. The company intends to use the proceeds from the financing to fund its growth plans. No operating metrics were disclosed in the article.

Participated · Series D · Jul 2008

BG Medicine is a life sciences company based in Waltham, Massachusetts focused on the discovery, development, and commercialization of novel biomarker-based diagnostics. The company recently launched the BGM Galectin-3 test for use in patients with heart failure. It also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. To support commercialization efforts and provide additional growth capital, BG Medicine secured a $15 million multi-draw senior secured term loan facility agented by GE Capital, Healthcare Financial Services. Company management said GE Capital was a trusted source of financing and structured a loan well-suited to further product development and commercialization plans. GE Capital's Healthcare Financial Services group has provided more than $60 billion in financing over ten years across healthcare sectors. BG Medicine develops molecular diagnostic tests built on a patented biomarker discovery platform that integrates measurement and analysis of proteins and metabolites. The company’s tests are intended to predict drug response, assess toxicity risk, identify or prognose disease, and monitor disease progression or therapy response. BG Medicine has a pipeline focused on cardiovascular disease, cancer and central nervous system disorders and ongoing joint initiatives with Merck, AstraZeneca, Abbott, Takeda, Humana, Philips and the U.S. FDA. The firm applies systems biology to discover and validate biomarkers and has created multiple product candidates from those efforts. Proceeds from the recent financing are planned to accelerate commercialization and the launch of the company’s first two diagnostic products and to continue discovery and development of additional candidates.